Cetera Advisors LLC Buys 1,719 Shares of Gilead Sciences, Inc. (GILD)

Cetera Advisors LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 67,018 shares of the biopharmaceutical company’s stock after acquiring an additional 1,719 shares during the period. Cetera Advisors LLC’s holdings in Gilead Sciences were worth $5,412,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in GILD. FMR LLC lifted its holdings in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Gilead Sciences by 26.6% in the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after purchasing an additional 100,741 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. Finally, Toronto Dominion Bank lifted its holdings in shares of Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after purchasing an additional 75,364 shares in the last quarter. Institutional investors own 75.84% of the company’s stock.

A number of analysts have recently issued reports on the company. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price for the company in a report on Monday. BMO Capital Markets increased their target price on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a report on Thursday. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the company a “hold” rating in a report on Wednesday. Citigroup restated a “buy” rating and issued a $105.00 target price (up previously from $103.00) on shares of Gilead Sciences in a report on Thursday. Finally, TheStreet lowered Gilead Sciences from a “b-” rating to a “c” rating in a report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $86.56.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Chairman John C. Martin sold 50,000 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the transaction, the chairman now directly owns 3,046,766 shares in the company, valued at $254,587,766.96. The disclosure for this sale can be found here. Insiders have sold 578,333 shares of company stock worth $44,100,508 over the last three months. Company insiders own 1.30% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $79.32 on Friday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $89.54. The company has a quick ratio of 3.56, a current ratio of 3.55 and a debt-to-equity ratio of 1.10. The firm has a market cap of $103,590.00, a price-to-earnings ratio of 22.79, a PEG ratio of -1.73 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s quarterly revenue was down 18.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.70 earnings per share. research analysts predict that Gilead Sciences, Inc. will post 6.46 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a yield of 2.87%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 59.77%.

TRADEMARK VIOLATION WARNING: This report was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.com-unik.info/2018/02/11/cetera-advisors-llc-buys-1719-shares-of-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit